Adamas Pharmaceuticals Inc (ADMS): William W. Ericson , director 10% owner of Adamas Pharmaceuticals Inc purchased 84,376 shares on Sep 12, 2016. The Insider buying transaction was reported by the company on Sep 14, 2016 to the Securities and Exchange Commission. The shares were purchased at $15.60 per share for a total value of $1,314,729.62 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Sep 9, 2016, William W. Ericson (director 10% owner) purchased 60,846 shares at $15.68 per share price.On Apr 20, 2016, Natalie Mcclure (SVP, Product Development) sold 36,000 shares at $18.50 per share price.Also, On Dec 9, 2015, Ivan M Lieberburg (director) sold 3,000 shares at $16.23 per share price.On Jun 17, 2015, Richard H Booth (director) sold 1,000 shares at $19.32 per share price.
Adamas Pharmaceuticals Inc: On Monday, Sep 12, 2016 heightened volatility was witnessed in Adamas Pharmaceuticals Inc which led to swings in the share price. The shares opened for trading at $15.12 and hit $15.85 on the upside , eventually ending the session at $15.77, with a gain of 4.37% or 0.66 points. The heightened volatility saw the trading volume jump to 171,380 shares. The 52-week high of the share price is $31.84 and the company has a market cap of $346 M . The 52-week low of the share price is at $12.02.
Company has been under the radar of several Street Analysts.Adamas Pharmaceuticals Inc is Reiterated by Mizuho to Buy and the brokerage firm has raised the Price Target to $ 26 from a previous price target of $22 .The Rating was issued on Sep 8, 2016.Adamas Pharmaceuticals Inc is Initiated by Noble Financial to Buy and the brokerage firm has set the Price Target at $25. The Rating was issued on Jun 17, 2016.
Adamas Pharmaceuticals Inc. is a specialty pharmaceutical company focused on development and commercialization of therapeutics targeting chronic disorders of central nervous systems (CNS). It is engaged in modifying pharmacokinetic (PK) profiles of approved drugs to create therapeutics for use alone and in fixed-dose combination products. It develops its lead product ADS-5102 (amantadine hydrochloride) for a complication associated with treatment of Parkinson’s disease known as levodopa induced dyskinesia and as a treatment for one or more additional CNS indications. Its other product candidate is ADS-8704. Through a partnership with Forest Laboratories Holdings Limited its portfolio includes two drugs commercially available in the United States: Namzaric (memantine hydrochloride extended-release and donepezil hydrochloride) and Namenda XR (memantine hydrochloride) extended release and donepezil hydrochloride) and Namenda XR (memantine hydrochloride) extended release capsules.